Skip to Content
Merck
CN
  • Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.

Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase.

Bioorganic & medicinal chemistry letters (2011-07-02)
Christophe Antczak, David Shum, Bhramdeo Bassit, Mark G Frattini, Yueming Li, Elisa de Stanchina, David A Scheinberg, Hakim Djaballah
ABSTRACT

Selective inhibitors of human peptide deformylase (HsPDF) are predicted to constitute a new class of antitumor agents. We report the identification of benzofuran-4,5-diones as the first known selective HsPDF inhibitors and we describe their selectivity profile in a panel of metalloproteases. We characterize their structure-activity relationships for antitumor activity in a panel of cancer cell lines, and we assess their in vivo efficacy in a mouse xenograft model. Our results demonstrate that selective HsPDF inhibitors based on the benzofuran-4,5-dione scaffold constitute a novel class of antitumor agents that are potent in vitro and in vivo.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2,3-Benzofuran, 99%
Sigma-Aldrich
Ciprofloxacin, ≥98% (HPLC)
Supelco
Ciprofloxacin, VETRANAL®, analytical standard